Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

GAPDH Post-Translational Modifications as Molecular Switches in Cancer Metabolism and Tumor Microenvironment Remodeling.

Created on 20 Nov 2026

Authors

Ziqi Jiang, Zhengrong Zhou, Xin Qian, Qian Chen, Pan Huang

Published in

Cancer medicine. Volume 15. Issue 11.

Abstract

Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a multifunctional protein that participates in cancer metabolism, apoptosis, DNA repair, angiogenesis, and immune regulation beyond its canonical glycolytic role. However, how distinct post-translational modifications (PTMs) coordinate GAPDH functional transitions and determine its diverse biological roles in cancer remains incompletely understood. In this review, we summarize current advances in GAPDH PTMs, including methylation, phosphorylation, acetylation, ubiquitination, S-nitrosylation, serotonylation, crotonylation, lactylation, and succinylation, with emphasis on modification sites, regulatory enzymes, cellular contexts, and functional consequences. We propose a PTM-driven molecular switching model in which different cellular stimuli induce specific GAPDH modifications to regulate its enzymatic activity, subcellular localization, and protein interactions. Representative mechanisms include Src-mediated Tyr41 phosphorylation promoting DNA repair and 5-fluorouracil resistance in colorectal cancer, K254 and K160 acetylation regulating glycolytic activity and apoptosis through distinct cellular contexts, Parkin-mediated ubiquitination controlling mitophagy and metabolic reprogramming, and Gln262 serotonylation enhancing CD8+ T-cell glycolytic function and antitumor immunity. We further discuss the crosstalk among GAPDH PTMs and critically evaluate the current evidence, limitations, and therapeutic implications of GAPDH modification-based regulation. Although GAPDH PTMs represent promising targets for cancer intervention, current evidence is mainly derived from cellular and preclinical models, and PTM-specific therapeutic strategies remain limited. Further studies are required to clarify the cancer-specific functions and clinical relevance of GAPDH PTM networks.

PMID:
43059164
Bibliographic data and abstract were imported from PubMed on 20 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 1
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement